Speed Up Your Time-To-Clinic With Our Advanced 4Cell® CHO Platform Services
Proprietary and superior CHO cell line development technology that ensures a robust and scalable bioprocess with high product yield (up to 10g/L for monoclonal antibodies) and quality.
From DNA to Research Cell Bank (RCB) in only 9 weeks. No need for time-consuming media and process optimization or scalability studies. Regulatory ready documentation package.
More than 240 cell line development projects. Benefit from our know-how and experience and get your cell line right the first time.
No hidden fees, no cancelation fees, no milestone payments.
Rapidly Generate High-Yielding, Stable Cell Lines
Sartorius offers a complete service with industry-leading technology aimed at the commercial manufacturing of protein therapeutics. Tour our state-of-the-art facility which features special laboratories designed to develop cell lines.
4Cell® CHO Platform Features
The 4Cell® CHO Platform Bundles Services and Media in a GMP Manufacturing-Ready Solution
The combination of Sartorius’ industry-leading technologies and services into one integrated solution accelerates your program and puts your molecule on the path to success.
The unique 4Cell® CHO Platform consists of the following Sartorius solutions:
Sartorius’ CHO Cell Line Development service targets commercial manufacturing of biopharmaceuticals. Our unparalleled cell line development technology combines 4 key components: Expression vector, host cell line, 4Cell® SmartCHO media, and upstream process design.
Sartorius’ protein characterization services are scaled to each phase of drug development. These services include development, qualification and validation of product characterization assays, such as cell-based potency assays, binding assays and physicochemical tests.
The Sartorius cell banking platform was designed as a closed, sterile, single-use system with automated filling into vials to generate large banks. Plus, Sartorius has extensive experience in characterization of cell banks used in production of biologic drugs for protein-based therapies.
With the freedom to use the CMO of their choice for production, multiple satisfied clients have benefited from Sartorius CLD Service. The service offers exceptional flexibility at a reduced cost and enables clients to overcome typical obstacles that can delay manufacturing a first GMP batch.